John Libbey Eurotext

Annales de Biologie Clinique


Placental growth factor (PlGF) and sFlt-1 during pregnancy: physiology, assay and interest in preeclampsia Volume 74, issue 3, Mai-Juin 2016


  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4


1 Inserm UMR-S 1139, Physiopathologie et pharmacotoxicologie placentaire humaine, Paris, France
2 Département de gynécologie obstétrique I, Maternité Port-Royal, Centre hospitalier universitaire Cochin-Broca-Hôtel-Dieu, Groupe Hospitalier Universitaire Ouest, AP-HP, Paris, France
3 Fondation Premup, Paris, France
4 DHU Risques et grossesse, Paris, France
5 PRES Sorbonne Paris-Cité, Université Paris-Descartes, Paris, France
6 Département de gynécologie obstétrique, CHI Créteil, CRC CHI Créteil, Université Paris Est Créteil, France
7 Laboratoire d’hormonologie, Centre hospitalier universitaire Cochin Broca-Hôtel-Dieu, Groupe hospitalier universitaire Ouest, AP-HP, Paris, France
* Tirés à part

The placental growth factor (PlGF) and its soluble receptor (sFlt-1) are circulating angiogenic factors. During pregnancy these factors are released by the placenta into the maternal circulation. Preeclampsia affects 2-7% of pregnant women according to their risk factors and is characterized by high blood pressure and the onset of de novo proteinuria in the second half of pregnancy. Alterations of the sFlt-1/PlGF ratio in preeclampsia correlate with the diagnosis and adverse outcomes, particularly when the disease presents prematurely (<34 weeks). These factors can be assayed in maternal blood and measuring the sFlt-1/PlGF ratio is now available. We propose in this work to update the knowledge of these two molecules, describe their roles and evolution during normal pregnancy and preeclampsia, and finally to focus on the available assays.